Get started
DEFENCE THERAPEUTICS INC.DEFENCE THERAPEUTICS INC.DEFENCE THERAPEUTICS INC.

DEFENCE THERAPEUTICS INC.

No trades
See on Supercharts
Overview
Financials News Ideas Technicals

DTC chart

Key stats

Market capitalization
‪57.65 M‬CAD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.31CAD
Net income
‪−6.76 M‬CAD
Revenue
—
Shares float
‪42.53 M‬
Beta (1Y)
−0.22

About DEFENCE THERAPEUTICS INC.

Sector
Health Technology
CEO
Sébastien Plouffe
Headquarters
Vancouver
Website
defencetherapeutics.com
Founded
2017
FIGI
BBG010VMGQF4
Defence Therapeutics, Inc. engages in the research and development of anti-body drug conjugates. It focuses on enhancing intracellular delivery of biological or biosimilar therapeutic drugs targeting cancer and infectious diseases. The company was founded by Simon Beaudoin and Sébastien Plouffe on July 18, 2017 and is headquartered in Vancouver, Canada.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of DTC is 1.42 CAD — it has decreased by 9.55% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NEO exchange DEFENCE THERAPEUTICS INC. stocks are traded under the ticker DTC.
DTC stock is 10.56% volatile and has beta coefficient of −0.22. Check out the list of the most volatile stocks — is DEFENCE THERAPEUTICS INC. there?
Yes, you can track DEFENCE THERAPEUTICS INC. financials in yearly and quarterly reports right on TradingView.
DTC stock has fallen by 3.40% compared to the previous week, the month change is a 14.97% fall, over the last year DEFENCE THERAPEUTICS INC. has showed a 61.10% decrease.
DTC net income for the last quarter is ‪−8.32 M‬ CAD, while the quarter before that showed ‪−2.20 M‬ CAD of net income which accounts for −278.67% change. Track more DEFENCE THERAPEUTICS INC. financial stats to get the full picture.
Today DEFENCE THERAPEUTICS INC. has the market capitalization of ‪55.40 M‬, it has increased by 3.38% over the last week.
No, DTC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, DTC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DEFENCE THERAPEUTICS INC. stock right from TradingView charts — choose your broker and connect to your account.
DTC reached its all-time high on Sep 10, 2021 with the price of 8.10 CAD, and its all-time low was 1.30 CAD and was reached on Apr 10, 2024.
See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DEFENCE THERAPEUTICS INC. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DEFENCE THERAPEUTICS INC. stock shows the strong sell signal. See more of DEFENCE THERAPEUTICS INC. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.